Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours

Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy

(2013) D. Gerald et al.   CANCER RESEARCH

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

(2012) Moritz Felcht et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis

(2012) Tanja Holopainen et al.   JNCI-Journal of the National Cancer Institute

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF

(2011) Charlotte Rolny et al.   CANCER CELL

Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?

(2011) Katrien De Bock et al.   Nature Reviews Clinical Oncology

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

(2010) V Goede et al.   BRITISH JOURNAL OF CANCER

Double Antiangiogenic Protein, DAAP, Targeting VEGF-A and Angiopoietins in Tumor Angiogenesis, Metastasis, and Vascular Leakage

(2010) Young Jun Koh et al.   CANCER CELL

Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth

(2010) H. Hashizume et al.   CANCER RESEARCH

Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas

(2010) S.-S. Chae et al.   CLINICAL CANCER RESEARCH

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

(2009) Patrick Nasarre et al.   CANCER RESEARCH

Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization

(2009) Massimiliano Mazzone et al.   CELL

Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition

(2008) D. T. Dang et al.   CANCER RESEARCH

Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide

(2008) Q. Zhou et al.   CLINICAL CANCER RESEARCH

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

(2008) Qingyu Zhou et al.   NEURO-ONCOLOGY